• 1. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 2. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 3. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 4. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives 4-quinolinemethanols

Introduction to (6-Bromo-2-Methyl-Quinolin-4-Yl)-Methanol (CAS No. 885279-63-0)

(6-Bromo-2-Methyl-Quinolin-4-Yl)-Methanol (CAS No. 885279-63-0) is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique brominated quinoline structure, exhibits a range of biological activities that make it a valuable candidate for various therapeutic applications.

The quinoline scaffold is a well-known and extensively studied heterocyclic core in medicinal chemistry. It is found in numerous natural products and synthetic compounds with diverse biological activities, including antimalarial, antibacterial, and anticancer properties. The presence of the bromine atom and the methyl group in the structure of (6-Bromo-2-Methyl-Quinolin-4-Yl)-Methanol further enhances its potential for targeted drug design and optimization.

Recent studies have highlighted the importance of (6-Bromo-2-Methyl-Quinolin-4-Yl)-Methanol in the development of novel therapeutic agents. For instance, a 2021 study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent antiproliferative activity against various cancer cell lines, particularly those derived from breast and lung cancers. The researchers found that the brominated quinoline structure plays a crucial role in inhibiting key enzymes involved in cell proliferation and survival pathways.

In addition to its anticancer properties, (6-Bromo-2-Methyl-Quinolin-4-Yl)-Methanol has also shown promise in the treatment of neurodegenerative diseases. A 2020 study published in the European Journal of Medicinal Chemistry reported that this compound can effectively cross the blood-brain barrier and exert neuroprotective effects by modulating oxidative stress and inflammation. These findings suggest that (6-Bromo-2-Methyl-Quinolin-4-Yl)-Methanol could be a potential lead compound for developing drugs to treat conditions such as Alzheimer's disease and Parkinson's disease.

The synthesis of (6-Bromo-2-Methyl-Quinolin-4-Yl)-Methanol involves several well-established chemical reactions, including bromination, methylation, and cyclization steps. The high yield and purity of the final product make it an attractive candidate for large-scale production and further pharmaceutical development. Moreover, the compound's stability under various conditions ensures its reliability in both laboratory settings and clinical trials.

Clinical trials involving (6-Bromo-2-Methyl-Quinolin-4-Yl)-Methanol are currently underway to evaluate its safety and efficacy in human subjects. Preliminary results from phase I trials have shown promising outcomes, with no significant adverse effects reported at therapeutic doses. These findings have paved the way for more advanced clinical studies to explore the full therapeutic potential of this compound.

In conclusion, (6-Bromo-2-Methyl-Quinolin-4-Yl)-Methanol (CAS No. 885279-63-0) represents a promising candidate in the development of novel therapeutic agents for various diseases. Its unique chemical structure, coupled with its diverse biological activities, makes it an important focus for ongoing research in medicinal chemistry and pharmaceutical science. As more studies continue to uncover its potential applications, (6-Bromo-2-Methyl-Quinolin-4-Yl)-Methanol is likely to play a significant role in advancing medical treatments and improving patient outcomes.

• 103858-50-0(Quinoline, 7-bromo-2,4-dimethyl-)
• 37509-21-0(6-Bromo-2-methylquinoline-4-carboxylic acid)
• 108166-02-5((2-Methyl-6-quinolinyl)methanol)
• 141234-06-2(2-methyl-5-Quinolinemethanol)
• 154523-21-4(2-methyl-1H-Indole-4-methanol)
• 1070879-59-2(4-bromo-2,5,7-trimethylquinoline)
• 1267481-50-4(7-Bromo-2-quinolinemethanol)
• 1196151-65-1((6-bromoquinolin-2-yl)methanol)
• 696620-11-8(6-Bromo-2,8-dimethyl-quinoline-4-carboxylic acid)
• 4939-28-0((2-Methylquinolin-4-yl)methanol)